专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP0752889B1 LIPOSOMES CONTAINING A X-RAY- OR ULTRASOUND CONTRAST AGENT 失效
标题翻译：脂质体含有X射线和超声造影剂
公开(公告)号：EP0752889B1
公开(公告)日：2002-06-26
申请号：EP95913223.4
申请日：1995-03-27
申请人： Nycomed Imaging AS , DAIICHI PHARMACEUTICAL CO., LTD.
发明人： KLAVENESS, Jo , BERG, Arne , JACOBSEN, Trond Vegard , RONGVED, Pal , EGE, Thorfinn , KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd. , YACHI, Kiyoto, Daiichi Pharmaceutical Co., Ltd.
IPC分类号： A61K49/00 , A61K49/04
CPC分类号： A61K49/227 , A61K49/0466 , A61K49/1812
摘要： The invention provides a diagnostic composition for administration to human or animal subjects the composition containing multilamellar liposomes, optionally together with unilamellar liposomes, the liposomes containing at least one imaging agent and being suspended in an aqueous medium containing said imaging agent, wherein the liposomes comprise a neutral phospholipid and a charged phospholipid, the average particle diameter of the liposomes is 50-3000 nm and the concentration of imaging agent in any aqueous phase filling the interior of the liposomes is substantially the same as that in the aqueous medium in which the liposomes are suspended. The contrast agents concerned are typically X-ray, MRI or ultrasound contrast agents.

2. 发明公开

EP0640347A1 ORAL VACCINE 失效
标题翻译： ORALE IMPFSTOFFE。
公开(公告)号：EP0640347A1
公开(公告)日：1995-03-01
申请号：EP93904375.8
申请日：1993-03-02
申请人： DAIICHI PHARMACEUTICAL CO., LTD.
发明人： TSUCHIYA, Seishi , ARAMAKI, Yukihiko , HARA, Toshifumi, 203, Tokyo College , KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd. , YACHI, Kiyoto, Daiichi Pharmaceutical Co., Ltd. , IKEUCHI, Tohru, Daiichi Pharmaceutical Co., Ltd.
IPC分类号： A61K39/00
CPC分类号： A61K9/127 , A61K9/1271 , A61K9/1272 , A61K39/39 , A61K47/544 , A61K47/549 , A61K47/6911 , A61K2039/542 , A61K2039/55555
摘要： An oral vaccine comprising a complex of an antigen with a lipid, wherein the lipid contains a phospholipid comprising a glycolipid and/or phosphatidylserine combined with mannose. The vaccine serves to produce efficiently an antibody against the above antigen after being orally administered to living organisms. It makes it possible to administer orally a microbial antigen or a weakly virulent microbe which has not been orally absorbable and has been incapable of producing an antibody thereagainst.
摘要翻译：一种口服疫苗，其包含抗原与脂质的复合物，其中所述脂质含有包含与甘露糖组合的糖脂和/或磷脂酰丝氨酸的磷脂。疫苗经口给予生物体后，有效地产生抗上述抗原的抗体。可以口服给予微生物抗原或弱毒性微生物，该微生物尚未经口可吸收并且不能产生抗体。

3. 发明公开

EP0893125A1 FINE GRAIN CARRIERS AND MEDICINAL COMPOSITION PREPARED WITH THE USE OF THE SAME 失效
标题翻译： FEINKÖRNIGERTRÄGERMATERIALUND DAMIT HERGESTELLTEN PHAMAZEUTISCHEN ZUSAMMENSETZUNGEN
公开(公告)号：EP0893125A1
公开(公告)日：1999-01-27
申请号：EP97904584.6
申请日：1997-02-20
申请人： DAIICHI PHARMACEUTICAL CO., LTD.
发明人： AKASHI, Mitsuru , KISHIDA, Akio , SAKUMA, Shinji, Daiichi Pharmaceutical Co., Ltd. , KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd.
IPC分类号： A61K47/30
CPC分类号： A61K47/32 , A61K9/1635
摘要： The present invention is directed to particulate carriers useful as drug carriers in a drug delivery system (DDS) and to pharmaceutical compositions making use of such carriers. The invention is characterized by the use, as the particulate carrier, of: graft copolymer (A) whose graft chain is poly N-alkylacrylamide chain, poly N-alkylmethacrylamide chain, etc.; and a composition containing a combination of the graft copolymer (A) and at least one graft copolymer selected from the group consisting of graft copolymers (B-1) having polyacrylic acid or polymethacrylic acid as the graft chain and graft copolymers (B-2) having a polyvinyl amine compound as the graft chain.
摘要翻译：本发明涉及用作药物递送系统（DDS）中的药物载体的颗粒载体和利用这种载体的药物组合物。本发明的特征在于使用接枝共聚物（A）作为颗粒载体，其接枝链是聚N-烷基丙烯酰胺链，聚N-烷基甲基丙烯酰胺链等; 和含有接枝共聚物（A）和至少一种选自具有聚丙烯酸或聚甲基丙烯酸作为接枝链的接枝共聚物（B-1）和接枝共聚物（B-2）的组合的组合物，具有聚乙烯胺化合物作为接枝链。

4. 发明公开

EP0953359A1 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION 失效
标题翻译：药物组合物口服
公开(公告)号：EP0953359A1
公开(公告)日：1999-11-03
申请号：EP97949114.9
申请日：1997-12-17
申请人： DAIICHI PHARMACEUTICAL CO., LTD.
发明人： TAKAHASHI, Masayuki, Daiichi Pharmaceut. Co., Ltd. , MORITA, Hiromi, Daiichi Pharmaceutical Co., Ltd. , KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd.
IPC分类号： A61K47/40
CPC分类号： A61K9/4858 , A61K47/14 , A61K47/40
摘要： The present invention is directed to a pharmaceutical composition for oral administration, comprising a basic drug, a lipophilic substance, and/or a cyclodextrin.
The composition exhibits improved peroral absorption of a basic drug which is difficult to be absorbed by oral administration.

5. 发明公开

EP0896816A1 LIPOSOME AND LIPOSOME DISPERSION 失效
标题翻译： LIPOSOM UND LIPOSOMDISPERSION
公开(公告)号：EP0896816A1
公开(公告)日：1999-02-17
申请号：EP97905406.1
申请日：1997-02-26
申请人： DAIICHI PHARMACEUTICAL CO., LTD.
发明人： YAMAUCHI, Hitoshi, Daiichi Pharmaceutical Co., Ltd , MORITA, Hiromi, Daiichi Pharmaceutical Co., Ltd. , KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd.
IPC分类号： A61K9/127 , A61K47/24 , A61K31/557
CPC分类号： A61K9/1272 , A61K9/1271
摘要： This invention aims at improving stability of drugs which have poor stability in aqueous solution, and the stability of such drugs are improved by incorporating the drugs in liposomes which have a sphingolipid as the main component of the liposomal membrane-constituting lipids.
摘要翻译：本发明旨在提高在水溶液中稳定性差的药物的稳定性，并且通过将药物掺入脂质体作为脂质体构成脂质的主要成分的脂质体来提高这些药物的稳定性。

6. 发明公开

EP1764102A1 QUINOLONE-CONTAINING MEDICINAL COMPOSITION 审中-公开
标题翻译： CHINOLON-HALTIGE MEDIZINISCHE ZUSAMMENSETZUNG
公开(公告)号：EP1764102A1
公开(公告)日：2007-03-21
申请号：EP05755839.7
申请日：2005-07-01
申请人： DAIICHI PHARMACEUTICAL CO., LTD.
发明人： YANO, Emi , KOBAYASHI, Hideo, Daiichi Pharmaceutical Co., Ltd. , KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd. , YAMAGUCHI, Yuri, Daiichi Pharmaceutical Co., Ltd. , JINDO, Toshimasa, Daiichi Pharmaceutical Co., Ltd. , NISHIMOTO, N., Daiichi Pharmaceutical Co., Ltd.
IPC分类号： A61K31/4709 , A61K47/02
CPC分类号： A61K31/4709 , A61K9/0019 , A61K33/06 , A61K33/14 , A61K47/02 , A61K2300/00
摘要： The present invention relates to a pharmaceutical solution comprising the following components (A) and (B):
(A) a compound represented by the following formula (1):

or a salt thereof, or a hydrate thereof; and
(B) a multivalent metal compound, wherein molar ratio of the component (B) to component (A) (the multivalent compound / component (B)) is 0.01 to 0.7. A pharmaceutical solution adapted for intravascular administration containing the quinolone compound at a therapeutically sufficient amount is provided, and this solution exhibits reduced toxicity even when the multivalent metal compound were incorporated at a reduced amount.
摘要翻译：本发明涉及包含以下组分（A）和（B）的药物溶液：（A）由下式（1）表示的化合物或其盐或其水合物：和（B）成分（B）与成分（A）（多价化合物/成分（B））的摩尔比为0.01〜0.7的多价金属化合物。提供了适于以治疗足够量含有喹诺酮化合物的血管内施用的药物溶液，并且即使当以降低的量掺入多价金属化合物时，该溶液也显示出降低的毒性。

7. 发明公开

EP0804925A1 LIPOSOME WITH INCREASED RETENTION VOLUME 失效
标题翻译： LIPOSOM MITERHÖHTEMRETENTIONSVOLUMEN
公开(公告)号：EP0804925A1
公开(公告)日：1997-11-05
申请号：EP95913349.7
申请日：1995-03-27
申请人： DAIICHI PHARMACEUTICAL CO., LTD.
发明人： KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd. , YACHI, Kiyoto, Daiichi Pharmaceutical Co., Ltd.
IPC分类号： A61K9/127 , A61K47/24 , B01J13/02
CPC分类号： A61K9/127
摘要： The present invention provides liposome preparations capable of efficiently holding water soluble substance particularly non-electrolytic water soluble substances.
Liposomes and suspensions thereof comprising multilamellar liposomes characterized in that the liposome membrane is formed from a neutral phospholipid comprising a substantially saturated fatty acid residue a charged phospholipid comprising a substantially saturated fatty acid residue, ratio of said neutral phospholipid and charged phospholipid is 200:1 to 3:1, weighted average particle size of the liposome is 50 nm to 3,000 nm, and an encapsulation capacity of the liposome (internal aqueous phase (volume)/lipids (weight)) is at least 5 mℓ/g.
The present liposome preparation can encapsulate an aqueous solution of a non-electrolytic water soluble substances with an encapsulation capacity (internal aqueous phase/lipids) of at least 5 mℓ/g.
摘要翻译：本发明提供能够有效保持水溶性物质，特别是非电解水溶性物质的脂质体制剂。包含多层脂质体的脂质体和悬浮液的特征在于脂质体膜由包含基本上饱和的脂肪酸残基的中性磷脂形成，包含基本上饱和的脂肪酸残基的带电磷脂，所述中性磷脂和带电磷脂的比例为200:1至如图3:1所示，脂质体的加权平均粒径为50nm〜3000nm，脂质体（内部水相（体积）/脂质（重量））的包封容量为5ml / g以上。本脂质体制剂可以包封具有至少5m l / g的包封能力（内部水相/脂质）的非电解水溶性物质的水溶液。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式